Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Total Liabilities (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Total Liabilities readings, the most recent being $1.4 million for Q4 2017.

  • On a quarterly basis, Total Liabilities fell 63.06% to $1.4 million in Q4 2017 year-over-year; TTM through Dec 2017 was $1.4 million, a 63.06% decrease, with the full-year FY2017 number at $1.4 million, down 63.06% from a year prior.
  • Total Liabilities hit $1.4 million in Q4 2017 for Eledon Pharmaceuticals, down from $2.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $8.0 million in Q2 2016 to a low of $1.4 million in Q4 2017.
  • Median Total Liabilities over the past 5 years was $4.7 million (2015), compared with a mean of $4.6 million.
  • Biggest five-year swings in Total Liabilities: soared 92.08% in 2014 and later crashed 63.06% in 2017.
  • Eledon Pharmaceuticals' Total Liabilities stood at $2.2 million in 2013, then soared by 92.08% to $4.2 million in 2014, then skyrocketed by 47.3% to $6.2 million in 2015, then crashed by 37.63% to $3.9 million in 2016, then crashed by 63.06% to $1.4 million in 2017.
  • The last three reported values for Total Liabilities were $1.4 million (Q4 2017), $2.4 million (Q3 2017), and $3.4 million (Q2 2017) per Business Quant data.